PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32098220-2	2020	Here, we report the protective effect of CG200745 (CG), a novel histone deacetylase inhibitor, on tubulointerstitial fibrosis in Col4a3-/- mice, a murine model of Alport syndrome.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	41-49	collagen, type IV, alpha 3	Mus musculus	129-135	
32098220-2	2020	Here, we report the protective effect of CG200745 (CG), a novel histone deacetylase inhibitor, on tubulointerstitial fibrosis in Col4a3-/- mice, a murine model of Alport syndrome.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	41-43	collagen, type IV, alpha 3	Mus musculus	129-135	
32098220-3	2020	Morphological analyses revealed CG treatment markedly alleviated kidney fibrosis in Col4a3-/- mice at the age of 7 weeks.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	32-34	collagen, type IV, alpha 3	Mus musculus	84-90	
32098220-4	2020	CG prevented the activation of transforming growth factor beta (TGFbeta) and its downstream SMAD signaling in the kidney of Col4a3-/- mice.	N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide	0-2	collagen, type IV, alpha 3	Mus musculus	124-130